You are here: Home > Therapeutics (former) > Cannabis and Cannabis Based Medicine Extracts: Additional Results

J Cannabis Ther 2003(3/4):153-161

Clinical Studies

Cannabis and Cannabis Based Medicine Extracts: Additional Results

Author
E. Russo

Abstract
This study reviews results in recent human clinical trials with cannabis based medicine extract (CBME), THC or cannabis. In a study performed at Queen's Square, London, both High THC and THC:CBD fixed ratio sublingual CBME demonstrated significant benefits on mean maximum cystometric capacity, mean daytime frequency of urination, frequency of nocturia, and mean daily episodes of incontinence in 11 multiple sclerosis patients with intractable lower urinary tract symptoms. A Phase II clinical study in Oxford, England with 24 MS and intractable pain patients was performed as a consecutive series of doubleblind, randomized, placebo-controlled single patient cross-over trials with sublingual CBME. Pain scores on visual analogue scales were significantly improved over placebo with both High THC and High CBD CBME. Subjectively, spasm was significantly improved with High THC and THC:CBD fixed ratio extracts. Spasticity was also subjectively improved with the High THC CBME. All three extracts significantly improved objective measures of spasticity, while the High THC and THC:CBD fixed ratio CBME significantly improved objective measures of spasm. In 34 intractable pain patients in Great Yarmouth, England, seven experienced substantial improvement over best available conventional treatment with CBME, 13 moderate, and eight some benefit. Many extended the range of their activities of daily living with acceptable levels of adverse effects. Preliminary results of four Phase III clinical trials of CBME by GW Pharmaceuticals have revealed highly significant benefits in neuropathic pain in MS, pain and sleep disturbance in MS and other neurological diseases, multiple symptoms in MS, and neuropathic pain in brachial plexus injury, respectively. Most patients attained good symptomatic control with minimal side effects. In Germany, a recent Phase II clinical trial has demonstrated significant benefit of oral THC in treatment of the tics of Tourette syndrome.


Keywords
Medical marijuana, cannabis, alternative delivery systems, THC, cannabidiol, CBD, multiple sclerosis, chronic pain, Tourette syndrome, brachial plexus injury, pharmacotherapy

PDF of the full text ]

Free Online Events 2020

You can find all information here.

The IACM is holding a free webinar series and a free anniversary online meeting from October to November 2020

All webinars will be held in English with subtitles in German, French, Spanish, and Portuguese. All webinars will be available online until March 2021

The anniversary online meeting to celebrate the IACM's 20th anniversary and to honour the 90th birthday of Raphael Mechoulam will be a live session only on the 5th November 2020.

The speakers in the webinar series are Donald I. Abrams, Bonni Goldstein, Franjo Grotenhermen, Manuel Guzmán, Raphael Mechoulam, Kirsten Müller-Vahl, Roger Pertwee, Daniele Piomelli, and Ethan Russo.

You can find all information here.
 

IACM Conference 2021

The 12th IACM Conference on Cannabinoids in Medicine will be held in Basel, Switzerland, from 14 to 16 October 2021.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.